Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Lockhart AC, et al. Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21. Invest New Drugs. 2019. PMID: 29781056 Free PMC article. Clinical Trial.
Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K. Zhou X, et al. Among authors: lockhart ac. J Clin Pharmacol. 2019 Sep;59(9):1204-1215. doi: 10.1002/jcph.1416. Epub 2019 Apr 15. J Clin Pharmacol. 2019. PMID: 30985952 Clinical Trial.
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, Luo J, Lockhart AC, Wang-Gillam A. Park H, et al. Among authors: lockhart ac. Cancer Chemother Pharmacol. 2021 Mar;87(3):337-347. doi: 10.1007/s00280-020-04183-0. Epub 2020 Nov 6. Cancer Chemother Pharmacol. 2021. PMID: 33159216 Free PMC article. Clinical Trial.
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J, Mita AC, Wade JL, Morris JC, Rixe O, Mita MM, Dedieu JF, Wack C, Kassalow L, Lockhart AC. Sarantopoulos J, et al. Among authors: lockhart ac. Cancer Chemother Pharmacol. 2014 Dec;74(6):1113-24. doi: 10.1007/s00280-014-2572-z. Epub 2014 Oct 12. Cancer Chemother Pharmacol. 2014. PMID: 25307552 Clinical Trial.
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Sarantopoulos J, et al. Among authors: lockhart ac. Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927. doi: 10.1007/s00280-016-3122-7. Epub 2016 Sep 28. Cancer Chemother Pharmacol. 2016. PMID: 27681579 Clinical Trial.
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML. Lockhart AC, et al. Clin Cancer Res. 2004 Jan 15;10(2):468-75. doi: 10.1158/1078-0432.ccr-0658-03. Clin Cancer Res. 2004. PMID: 14760067 Clinical Trial.
148 results